公司資料
Sutro Biopharma 股價、新聞與催化劑
- 股票代碼:
- STRO
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
22.28 USD (+8.79%)
收盤價
最後更新: 2026年8月17日
405M USD
市值
股價為何變動
As of Aug 17, 2026, STRO closed up 8.79% at $22.28. No new same-company headline was identified in the current news window.
公司概覽
Next-Generation ADC Company
Sutro Biopharma develops site-specific and novel-format antibody-drug conjugates for cancer. Its cell-free platform enables optimization of antibodies, linkers, and payloads and supports both single-payload and dual-payload ADC designs.
Wholly Owned ADC Pipeline
STRO-004 is a Tissue Factor-targeting ADC with a DAR8 topoisomerase I payload in a first-in-human Phase 1 dose-escalation study. STRO-006 targets ITGB6, while STRO-227 is a dual-payload ADC directed against PTK7.
Portfolio and Partnership Model
Sutro advances wholly owned ADCs while using partnerships to validate and monetize its technology. Collaborations provide external funding and potential milestone or royalty economics while the company retains direct ownership of selected oncology programs.
Cell-Free Platform Differentiation
The cell-free manufacturing system allows precise placement of non-natural amino acids and controlled attachment of linker-payload combinations. This capability supports consistent site-specific ADCs and formats that are difficult to generate through conventional cell-based expression.
Partnered Platform Validation
The first dual-payload immune-stimulating ADC developed through Sutro’s collaboration with Astellas has entered clinical development and begun patient dosing, providing external validation of the company’s multi-payload design capabilities.
未來催化劑
- Initial safety, pharmacokinetic, and early activity data from the Phase 1 dose-escalation study of STRO-004 were expected in mid-2026.
- An IND submission for STRO-006 is planned in 2026.
- An IND submission for STRO-227 is planned in 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。